{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008190","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2023-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.841716+00:00","generated_at":"2026-06-15T16:55:38.123542+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Editas Medicine Q1 net loss $49M; cash $401.8M; EDIT-301 on track for 20 SCD patients by year-end","bullets":["Net loss $49.0M ($0.71 per share), vs $50.5M ($0.74) in Q1 2022; collaboration revenue $9.9M up from $6.8M.","Cash & equivalents $401.8M as of March 31, 2023; expected to fund operations into 2025.","19 SCD patients enrolled in EDIT-301 RUBY trial; on track to dose 20 total by year-end; clinical update at EHA June 2023.","First TDT patient dosed in EDITHAL trial with successful neutrophil and platelet engraftment; data expected by year-end.","Appointed Emma Reeve as Board Chair and Elliott Levy as independent director; sold iNK programs to Shoreline Biosciences."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008190","json":"https://secwatch.observer/filing/0001558370-23-008190.json","markdown":"https://secwatch.observer/filing/0001558370-23-008190.md","text":"https://secwatch.observer/filing/0001558370-23-008190.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023008190/0001558370-23-008190-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023008190/edit-20230505x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T16:55:38.123542+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6e330c9a51eb5b1e68d9c58c68f3db3bd959f45b","claim":"Editas Medicine, Inc. reported the first quarter 2023 results: net income net loss attributable to common stockholders was $49.0 million, or $0.71 per share, EPS $0.71 per share.","evidence_excerpt":"Editas Medicine, Inc. (Nasdaq: EDIT), a clinical stage genome editing company, today reported business highlights and financial results for the first quarter 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650664/000155837023008190/0001558370-23-008190-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter 2023"},{"label":"Net income","value":"net loss attributable to common stockholders was $49.0 million, or $0.71 per share"},{"label":"EPS","value":"$0.71 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}